318 related articles for article (PubMed ID: 26091479)
1. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.
Ho CL; Lu CS; Chen JH; Chen YG; Huang TC; Wu YY
Medicine (Baltimore); 2015 Jun; 94(24):e993. PubMed ID: 26091479
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y
Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.
Porrata LF; Ristow KM; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski G; Thompson CA; Markovic SN
Leuk Lymphoma; 2014 Dec; 55(12):2728-38. PubMed ID: 24547705
[TBL] [Abstract][Full Text] [Related]
4. The prognostic impact of absolute lymphocyte and monocyte counts at diagnosis of diffuse large B-cell lymphoma in the rituximab era.
Aoki K; Tabata S; Yonetani N; Matsushita A; Ishikawa T
Acta Haematol; 2013; 130(4):242-6. PubMed ID: 23860478
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis.
Lin B; Chen C; Qian Y; Feng J
Leuk Lymphoma; 2015; 56(9):2563-8. PubMed ID: 25686648
[TBL] [Abstract][Full Text] [Related]
7. A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent.
Procházka V; Pytlík R; Janíková A; Belada D; Sálek D; Papajík T; Campr V; Fürst T; Furstova J; Trněný M
PLoS One; 2014; 9(7):e102594. PubMed ID: 25058337
[TBL] [Abstract][Full Text] [Related]
8. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
9. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma.
Markovic O; Popovic L; Marisavljevic D; Jovanovic D; Filipovic B; Stanisavljevic D; Matovina-Brko G; Hajder J; Matkovic T; Živkovic R; Stanisavljevic N; Todorović M; Petrovic D; Mihaljevic B
Eur J Intern Med; 2014 Mar; 25(3):296-302. PubMed ID: 24565533
[TBL] [Abstract][Full Text] [Related]
10. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.
Li YL; Pan YY; Jiao Y; Ning J; Fan YG; Zhai ZM
Ann Hematol; 2014 Apr; 93(4):617-26. PubMed ID: 24141331
[TBL] [Abstract][Full Text] [Related]
12. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy.
Song MK; Chung JS; Seol YM; Kim SG; Shin HJ; Choi YJ; Cho GJ; Shin DH
Ann Oncol; 2010 Jan; 21(1):140-4. PubMed ID: 19887468
[TBL] [Abstract][Full Text] [Related]
13. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).
Bento L; Díaz-López A; Barranco G; Martín-Moreno AM; Baile M; Martín A; Sancho JM; García O; Rodríguez M; Sánchez-Pina JM; Novelli S; Salar A; Bastos M; Rodríguez-Salazar MJ; González de Villambrosia S; Córdoba R; García-Recio M; Martínez-Serra J; Del Campo R; Luzardo H; García D; Hong A; Abrisqueta P; Sastre-Serra J; Roca P; Rodríguez J; Gutiérrez A;
Br J Haematol; 2020 Mar; 188(6):888-897. PubMed ID: 31782146
[TBL] [Abstract][Full Text] [Related]
14. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.
Li ZM; Huang JJ; Xia Y; Sun J; Huang Y; Wang Y; Zhu YJ; Li YJ; Zhao W; Wei WX; Lin TY; Huang HQ; Jiang WQ
PLoS One; 2012; 7(7):e41658. PubMed ID: 22911837
[TBL] [Abstract][Full Text] [Related]
15. The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma.
Beltrán BE; Paredes S; Cotrina E; Sotomayor EM; Castillo JJ
Leuk Res; 2018 Apr; 67():82-85. PubMed ID: 29477024
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
Li YL; Gu KS; Pan YY; Jiao Y; Zhai ZM
BMC Cancer; 2014 May; 14():341. PubMed ID: 24884604
[TBL] [Abstract][Full Text] [Related]
17. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
[TBL] [Abstract][Full Text] [Related]
18. Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.
Chae YS; Shin H; Sohn SK; Lee SJ; Moon JH; Kang BW; Kim JG; Yang DH; Lee JJ; Park TI
Leuk Lymphoma; 2012 Sep; 53(9):1757-63. PubMed ID: 22372848
[TBL] [Abstract][Full Text] [Related]
19. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.
Batty N; Ghonimi E; Feng L; Fayad L; Younes A; Rodriguez MA; Romaguera JE; McLaughlin P; Samaniego F; Kwak LW; Hagemeister FB
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):15-8. PubMed ID: 23137719
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
Yamamoto M; Watanabe K; Fukuda T; Miura O
Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
